Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Vertex Gets Quick FDA Approval Of Kalydeco; Prices New CF Drug At $294,000 Per Year

This article was originally published in The Pink Sheet Daily

Executive Summary

Kalydeco, an oral CFTR potentiator, becomes the first approved drug to address the underlying cause of cystic fibrosis, rather than just treating the disease’s symptoms.


Related Content

Cystic Fibrosis Drug Sales Should Soar; VX-661/Ivacaftor To Lead Way
Why Pricing Orkambi Below Kalydeco Is A Savvy Strategy For Vertex
Vertex’s Orkambi Approved With Broad Label For Cystic Fibrosis
Vertex’s Cystic Fibrosis Franchise Has Multiple Jump Points In 2015
Kalydeco Label Expansion Could Set New Precedent On FDA Flexibility
FDA Panel To Weigh Adequacy Of Efficacy Evidence For Kalydeco Label Expansion
Vertex’s Latest Bid For Kalydeco Label Expansion Heads To FDA Panel
The A-List: The Trend-Shaping Series A Financings Of 2013
In One Day, Change At Biotechs: Leiden To Replace Emmens At Vertex And At Amgen, Bradway Will Become CEO
Vertex's Cystic Fibrosis Drug Kalydeco Could See Speedy Review


Related Companies




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts